Skip to main content
SpringerLink
Log in

Neoadjuvant Therapy Prior to Radical Prostatectomy

  • Chapter
  • First Online:
Management of Advanced Prostate Cancer

  • 810 Accesses

Abstract

The terminology “neoadjuvant” stemmed from Greek “neos” that means new or before and the Latin language “adjuvāre” that means help or aid. Neoadjuvant therapy is the application of systemic care before operation or radiotherapy. Neoadjuvant therapy has some benefits in several tumors such as the bladder, testis, breast, colon, and lung. Conceptually, neoadjuvant therapy may decrease the size of the tumor before surgery or eliminate concealed micrometastases. In cases of neoadjuvant therapy before radiation therapy, shrinkage of the tumor is able to localize the site of the target with optimal doses while decreasing radiation exposure to surrounding normal tissue.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vallet B. Radical perineal prostatectomy subsequent to bilateral orchidectomy. Del Me J. 1944;16:18–20.

    Google Scholar 

  2. Green N, Bodner H, Broth E, Chiang C, Garrett J, Goldstein A, et al. Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys. 1984;10(7):971–6.

    Article  CAS  PubMed  Google Scholar 

  3. Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26(4):585–91.

    Article  PubMed  Google Scholar 

  4. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821–7.

    Article  PubMed  Google Scholar 

  5. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–73.

    Article  CAS  PubMed  Google Scholar 

  6. Bach C, Pisipati S, Daneshwar D, Wright M, Rowe E, Gillatt D, et al. The status of surgery in the management of high-risk prostate cancer. Nat Rev Urol. 2014;11(6):342–51.

    Article  PubMed  Google Scholar 

  7. Yuh B, Artibani W, Heidenreich A, Kimm S, Menon M, Novara G, et al. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol. 2014;65(5):918–27.

    Article  PubMed  Google Scholar 

  8. Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. 2010;76(3):710–4.

    Article  PubMed  Google Scholar 

  9. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.

    Article  CAS  PubMed  Google Scholar 

  10. Fair WR, Rabbani F, Bastar A, Betancourt J. Neoadjuvant hormone therapy before radical prostatectomy: update on the Memorial Sloan-Kettering Cancer Center Trials. Mol Urol. 1999;3(3):253–60.

    PubMed  CAS  Google Scholar 

  11. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38(6):706–13.

    Article  CAS  PubMed  Google Scholar 

  12. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;4:CD006019.

    Google Scholar 

  13. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001;166(2):500–6; discussion 6–7.

    Article  CAS  PubMed  Google Scholar 

  14. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008;180(2):565–70; discussion 70.

    Article  CAS  PubMed  Google Scholar 

  15. Thalgott M, Rack B, Horn T, Heck MM, Eiber M, Kubler H, et al. Detection of circulating tumor cells in locally advanced high-risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy. Anticancer Res. 2015;35(10):5679–85.

    PubMed  CAS  Google Scholar 

  16. Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308–23.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(33):3705–15.

    Article  CAS  Google Scholar 

  18. Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, et al. Neoadjuvant enzalutamide prior to prostatectomy. Clin Cancer Res. 2017;23(9):2169–76.

    Article  CAS  PubMed  Google Scholar 

  19. Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, et al. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol. 2009;181(1):81–7; discussion 7.

    Article  CAS  PubMed  Google Scholar 

  20. Vuky J, Porter C, Isacson C, Vaughan M, Kozlowski P, Picozzi V, et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer. 2009;115(4):784–91.

    Article  CAS  PubMed  Google Scholar 

  21. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, et al. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012;118(19):4777–84.

    Article  CAS  PubMed  Google Scholar 

  22. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014;106(11):pii: dju268.

    Article  CAS  Google Scholar 

  23. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017;23(5):551–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol. 1996;156(3):873–7.

    Article  CAS  PubMed  Google Scholar 

  25. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, et al. Neoadjuvant hormonal therapy: the Canadian experience. Urology. 1997;49(3A Suppl):56–64.

    Article  CAS  PubMed  Google Scholar 

  26. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167(1):112–6.

    Article  PubMed  Google Scholar 

  27. Selli C, Montironi R, Bono A, Pagano F, Zattoni F, Manganelli A, et al. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol. 2002;55(7):508–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002;90(6):561–6.

    Article  CAS  PubMed  Google Scholar 

  29. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170(3):791–4.

    Article  CAS  PubMed  Google Scholar 

  30. Prezioso D, Lotti T, Polito M, Montironi R. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int. 2004;72(3):189–95.

    Article  CAS  PubMed  Google Scholar 

  31. Gravina GL, Festuccia C, Galatioto GP, Muzi P, Angelucci A, Ronchi P, et al. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Urology. 2007;70(4):728–33.

    Article  PubMed  Google Scholar 

  32. Yee DS, Lowrance WT, Eastham JA, Maschino AC, Cronin AM, Rabbani F. Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. BJU Int. 2010;105(2):185–90.

    Article  CAS  PubMed  Google Scholar 

  33. Sayyid RK, Evans A, Hersey K, Maloni R, Hurtado-Coll A, Kulkarni G, et al. A phase II, randomized, open-label study of neoadjuvant degarelix versus LHRH agonist in prostate cancer patients prior to radical prostatectomy. Clin Cancer Res. 2017;23(8):1974–80.

    Article  CAS  PubMed  Google Scholar 

  34. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63(6):1138–42.

    Article  PubMed  Google Scholar 

  35. Friedman J, Dunn RL, Wood D, Vaishampayan U, Wu A, Bradley D, et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol. 2008;179(3):911–5; discussion 5–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Shepard DR, Dreicer R, Garcia J, Elson P, Magi-Galluzzi C, Raghavan D, et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol. 2009;181(4):1672–7; discussion 7.

    Article  CAS  PubMed  Google Scholar 

  37. Garzotto M, Higano CS, O’Brien C, Rademacher BL, Janeba N, Fazli L, et al. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer. 2010;116(7):1699–708.

    Article  CAS  PubMed  Google Scholar 

  38. Nosov A, Reva S, Petrov S, Mamijev E, Novikov R, Veliev E, et al. Neoadjuvant chemotherapy using reduced-dose docetaxel followed by radical prostatectomy for patients with intermediate and high-risk prostate cancer: a single-center study. Prostate. 2016;76(15):1345–52.

    Article  CAS  PubMed  Google Scholar 

  39. Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001;57(2):281–5.

    Article  CAS  PubMed  Google Scholar 

  40. Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana J, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology. 2003;61(4):774–80.

    Article  PubMed  Google Scholar 

  41. Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int. 2007;100(2):274–80.

    Article  CAS  PubMed  Google Scholar 

  42. Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJ, Areal J, et al. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer. 2009;101(8):1248–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Narita S, Tsuchiya N, Kumazawa T, Maita S, Numakura K, Obara T, et al. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol. 2012;10:1.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Silberstein JL, Poon SA, Sjoberg DD, Maschino AC, Vickers AJ, Bernie A, et al. Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer. BJU Int. 2015;116(1):50–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res. 2006;12(1):152–8.

    Article  CAS  PubMed  Google Scholar 

  46. Vuky J, Corman JM, Porter C, Olgac S, Auerbach E, Dahl K. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer. Oncologist. 2013;18(6):687–8.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Kumon H, Ariyoshi Y, Sasaki K, Sadahira T, Araki M, Ebara S, et al. Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy. Cancer Gene Ther. 2016;23(11):400–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    Se Young Choi & Choung Soo Kim

Authors
  1. Se Young Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Choung Soo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Choung Soo Kim .

Editor information

Editors and Affiliations

  1. Department of Urology, Asan Medical Center, Seoul, Soul-t´ukpyolsi, Korea (Republic of)

    Choung Soo Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Choi, S.Y., Kim, C.S. (2018). Neoadjuvant Therapy Prior to Radical Prostatectomy. In: Kim, C. (eds) Management of Advanced Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-6943-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-6943-7_3

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-6942-0

  • Online ISBN: 978-981-10-6943-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation